Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Despite the evolution of the therapeutic arsenal for the treatment of multiple myeloma (MM) over the past decade, autologous stem-cell transplantation (ASCT) remains an integral part of the treatment of patients with both newly diagnosed and relapsed MM. The advent of novel therapies, such as immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies, has led to unprecedented levels of deep hematologic responses. Nonetheless, studies show that ASCT has an additive effect leading to additional deepening of responses. As the therapeutic agents for MM continue to evolve, the timing, duration, and sequence of their use in combination with ASCT will be crucial to understand to obtain the deepest response and survival benefit for patients with MM. This review aims to discuss the role of ASCT for the management of MM, with a particular focus on the role of ASCT in the context of novel therapies and minimal residual disease.

Original languageEnglish (US)
Pages (from-to)56-66
Number of pages11
JournalJCO Oncology Practice
Volume16
Issue number2
DOIs
StatePublished - Feb 1 2020

ASJC Scopus subject areas

  • Health Policy
  • Oncology
  • Oncology(nursing)

Fingerprint Dive into the research topics of 'Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies'. Together they form a unique fingerprint.

  • Cite this